tiprankstipranks
Trending News
More News >
Bluebird bio Inc (BLUE)
NASDAQ:BLUE
US Market

Bluebird Bio (BLUE) Stock Forecast & Price Target

Compare
2,842 Followers
See the Price Targets and Ratings of:

BLUE Analyst Ratings

Moderate Buy
1Ratings
Moderate Buy
1 Buy
0 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Bluebird
Bio
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BLUE Stock 12 Month Forecast

Average Price Target

$8.00
▲(60.97%Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Bluebird Bio in the last 3 months. The average price target is $8.00 with a high forecast of $8.00 and a low forecast of $8.00. The average price target represents a 60.97% change from the last price of $4.97.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","32":"$32","10.25":"$10.25","17.5":"$17.5","24.75":"$24.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$8.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,10.25,17.5,24.75,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2024","6":"Oct<br/>2024","9":"Feb<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.97,5.203076923076923,5.436153846153846,5.669230769230769,5.9023076923076925,6.135384615384615,6.368461538461538,6.601538461538461,6.834615384615384,7.067692307692308,7.30076923076923,7.533846153846154,7.766923076923077,{"y":8,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.97,5.203076923076923,5.436153846153846,5.669230769230769,5.9023076923076925,6.135384615384615,6.368461538461538,6.601538461538461,6.834615384615384,7.067692307692308,7.30076923076923,7.533846153846154,7.766923076923077,{"y":8,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.97,5.203076923076923,5.436153846153846,5.669230769230769,5.9023076923076925,6.135384615384615,6.368461538461538,6.601538461538461,6.834615384615384,7.067692307692308,7.30076923076923,7.533846153846154,7.766923076923077,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":31.3,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.8,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.19,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.51,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.6,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.23,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.41,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.34,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.08,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.05,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.97,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$8.00Average Price Target$8.00Lowest Price Target$8.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on BLUE
TipRanks AITipRanks
Not Ranked
TipRanks
$5
Hold
0.60%
Upside
Reiterated
06/05/25
Bluebird Bio's overall stock score is primarily impacted by its financial instability and negative valuation metrics, which suggest high risk. However, the recent acquisition by Carlyle and SK Capital could provide the necessary capital and strategic direction to address these challenges, supported by some positive technical indicators.
Barclays Analyst forecast on BLUE
Gena WangBarclays
Barclays
$8
Buy
60.97%
Upside
Reiterated
05/15/25
Barclays Remains a Buy on Bluebird Bio (BLUE)
Wells Fargo Analyst forecast on BLUE
Yanan ZhuWells Fargo
Wells Fargo
$40$5
Hold
0.60%
Upside
Reiterated
02/21/25
bluebird bio (BLUE) PT Lowered to $5 at Wells FargoWells Fargo analyst Yanan Zh lowered the price target on bluebird bio (NASDAQ: BLUE) to $5.00 (from $40.00) while maintaining a Equal Weight rating.
RBC Capital Analyst forecast on BLUE
Luca IssiRBC Capital
RBC Capital
$80$8
Hold
60.97%
Upside
Reiterated
01/07/25
Bluebird Bio price target lowered to $8 at RBC Capital on 'limited cash runway'Bluebird Bio price target lowered to $8 at RBC Capital on 'limited cash runway'
Leerink Partners Analyst forecast on BLUE
Mani ForooharLeerink Partners
Leerink Partners
$1$10
Hold
101.21%
Upside
Reiterated
01/03/25
Analysts Offer Insights on Healthcare Companies: Cencora (NYSE: COR) and Bluebird Bio (NASDAQ: BLUE)
Bank of America Securities Analyst forecast on BLUE
Jason GerberryBank of America Securities
Bank of America Securities
$60$10
Hold
101.21%
Upside
Downgraded
11/15/24
Bluebird Bio downgraded to Neutral from Buy at BofABluebird Bio downgraded to Neutral from Buy at BofA
Oppenheimer Analyst forecast on BLUE
Mark BreidenbachOppenheimer
Oppenheimer
Hold
Reiterated
08/15/24
Oppenheimer reiterates Perform Rating on bluebird bio (BLUE)Oppenheimer analyst Mark Breidenbach reiterated a Perform rating on bluebird bio (NASDAQ: BLUE).
Morgan Stanley Analyst forecast on BLUE
Jeffrey HungMorgan Stanley
Morgan Stanley
$100
Hold
1912.07%
Upside
Reiterated
08/14/24
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on BLUE
TipRanks AITipRanks
Not Ranked
TipRanks
$5
Hold
0.60%
Upside
Reiterated
06/05/25
Bluebird Bio's overall stock score is primarily impacted by its financial instability and negative valuation metrics, which suggest high risk. However, the recent acquisition by Carlyle and SK Capital could provide the necessary capital and strategic direction to address these challenges, supported by some positive technical indicators.
Barclays Analyst forecast on BLUE
Gena WangBarclays
Barclays
$8
Buy
60.97%
Upside
Reiterated
05/15/25
Barclays Remains a Buy on Bluebird Bio (BLUE)
Wells Fargo Analyst forecast on BLUE
Yanan ZhuWells Fargo
Wells Fargo
$40$5
Hold
0.60%
Upside
Reiterated
02/21/25
bluebird bio (BLUE) PT Lowered to $5 at Wells FargoWells Fargo analyst Yanan Zh lowered the price target on bluebird bio (NASDAQ: BLUE) to $5.00 (from $40.00) while maintaining a Equal Weight rating.
RBC Capital Analyst forecast on BLUE
Luca IssiRBC Capital
RBC Capital
$80$8
Hold
60.97%
Upside
Reiterated
01/07/25
Bluebird Bio price target lowered to $8 at RBC Capital on 'limited cash runway'Bluebird Bio price target lowered to $8 at RBC Capital on 'limited cash runway'
Leerink Partners Analyst forecast on BLUE
Mani ForooharLeerink Partners
Leerink Partners
$1$10
Hold
101.21%
Upside
Reiterated
01/03/25
Analysts Offer Insights on Healthcare Companies: Cencora (NYSE: COR) and Bluebird Bio (NASDAQ: BLUE)
Bank of America Securities Analyst forecast on BLUE
Jason GerberryBank of America Securities
Bank of America Securities
$60$10
Hold
101.21%
Upside
Downgraded
11/15/24
Bluebird Bio downgraded to Neutral from Buy at BofABluebird Bio downgraded to Neutral from Buy at BofA
Oppenheimer Analyst forecast on BLUE
Mark BreidenbachOppenheimer
Oppenheimer
Hold
Reiterated
08/15/24
Oppenheimer reiterates Perform Rating on bluebird bio (BLUE)Oppenheimer analyst Mark Breidenbach reiterated a Perform rating on bluebird bio (NASDAQ: BLUE).
Morgan Stanley Analyst forecast on BLUE
Jeffrey HungMorgan Stanley
Morgan Stanley
$100
Hold
1912.07%
Upside
Reiterated
08/14/24
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bluebird Bio

1 Month
xxx
Success Rate
9/23 ratings generated profit
39%
Average Return
-0.30%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 39.13% of your transactions generating a profit, with an average return of -0.30% per trade.
3 Months
xxx
Success Rate
13/23 ratings generated profit
57%
Average Return
+4.81%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 56.52% of your transactions generating a profit, with an average return of +4.81% per trade.
1 Year
Gena WangBarclays
Success Rate
9/23 ratings generated profit
39%
Average Return
+20.45%
reiterated a buy rating last month
Copying Gena Wang's trades and holding each position for 1 Year would result in 39.13% of your transactions generating a profit, with an average return of +20.45% per trade.
2 Years
xxx
Success Rate
9/23 ratings generated profit
39%
Average Return
+26.30%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 39.13% of your transactions generating a profit, with an average return of +26.30% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BLUE Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
May 25
Jun 25
Strong Buy
4
3
2
2
2
Buy
0
0
0
0
0
Hold
8
11
7
6
4
Sell
1
1
0
0
0
Strong Sell
0
0
0
0
0
total
13
15
9
8
6
In the current month, BLUE has received 2 Buy Ratings, 4 Hold Ratings, and 0 Sell Ratings. BLUE average Analyst price target in the past 3 months is 8.00.
Each month's total comprises the sum of three months' worth of ratings.

BLUE Financial Forecast

BLUE Earnings Forecast

Next quarter’s earnings estimate for BLUE is -$2.52 with a range of -$2.52 to -$2.52. The previous quarter’s EPS was -$2.98. BLUE beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year BLUE has Outperformed its overall industry.
Next quarter’s earnings estimate for BLUE is -$2.52 with a range of -$2.52 to -$2.52. The previous quarter’s EPS was -$2.98. BLUE beat its EPS estimate 66.67% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year BLUE has Outperformed its overall industry.

BLUE Sales Forecast

Next quarter’s sales forecast for BLUE is $38.00M with a range of $38.00M to $38.00M. The previous quarter’s sales results were $38.71M. BLUE beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.48% of the time in the same period. In the last calendar year BLUE has Preformed in-line its overall industry.
Next quarter’s sales forecast for BLUE is $38.00M with a range of $38.00M to $38.00M. The previous quarter’s sales results were $38.71M. BLUE beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.48% of the time in the same period. In the last calendar year BLUE has Preformed in-line its overall industry.

BLUE Stock Forecast FAQ

What is BLUE’s average 12-month price target, according to analysts?
Based on analyst ratings, Bluebird bio Inc’s 12-month average price target is 8.00.
    What is BLUE’s upside potential, based on the analysts’ average price target?
    Bluebird bio Inc has 60.97% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is BLUE a Buy, Sell or Hold?
          Bluebird bio Inc has a consensus rating of Moderate Buy which is based on 1 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Bluebird bio Inc’s price target?
            The average price target for Bluebird bio Inc is 8.00. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $8.00 ,the lowest forecast is $8.00. The average price target represents 60.97% Increase from the current price of $4.97.
              What do analysts say about Bluebird bio Inc?
              Bluebird bio Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
                How can I buy shares of BLUE?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis